Benjamin Cowen, PhD, MBA

Philadelphia, Pennsylvania, United States
Dr. Cowen has over 20 years of pharmaceutical/biotech experience with a broad background spanning Business Development, Finance, R&D Portfolio Management, Marketing, and Sales. He has also worked across the spectrum including large pharma, mid-sized pharma and small companies.

At Merck for 14 years, he worked in Business Development leading both search & evaluation and transaction negotiations. He was the R&D Portfolio Management Director for Oncology. In Marketing, he was a Product Manager in hospital antibacterials. In Sales, he was an HIV Sales Representative and Medical Science Liaison.

At Shire Dr. Cowen led Portfolio Management and the annual Strategic Planning process.

At PDS Biotechnology, a clinical stage cancer vaccine company, he was VP of Business Development.

At Milestone Pharmaceuticals, a VC funded company developing breakthrough cardiovascular products, Dr. Cowen was VP of Corporate Development where he led Business Development, Commercial and played a key role in $17 M Series B financing round led by Domain Associates.

Currently, Dr. Cowen is CEO at ImmunoMet Therapeutics Inc., a VC funded company targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Dr. Cowen joined ImmunoMet in 2016 as COO as was promoted to CEO a year later.

Dr. Cowen served on the Board of Directors of Atrin Pharmaceuticals, an early stage oncology biotech, from 2012-2018 and currently serves on the Board of Directors of INCON, a public Korean healthcare holding company.

Dr. Cowen originally trained as research scientist and was an NIH Postdoctoral Fellow at the University of Pennsylvania. He holds a BA in Physics with high honors from Brandeis University, a PhD in Biophysics from the University of Illinois and an MBA in Strategy and Finance from Carnegie Mellon University.
Speaking In
8:30 AM - 9:40 AM
Tuesday, October 22
As the industry continues to do revolutionary research on cancer, a host of new treatment options…
10:30 AM - 10:45 AM
Tuesday, October 22
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and…